X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TAK-919
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-919
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
This interim analysis showed that binding antibody and neutralizing antibody titers were elevated at 28 days after the second dose in 100% of people vaccinated with two 0.5ml doses of TAK-919 given 28 days apart.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bordetella pertussis protective antigen,Diphtheria toxoid,Tetanus toxoid
Therapeutic Area: Infections and Infectious Diseases Product Name: Squarekids
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination March 31, 2021
Details:
Daiichi Sankyo will terminate its marketing alliance agreement for the Squarekids® subcutaneous injection syringe, a tetravalent combination vaccine and its joint development agreement on pentavalent combination vaccine with Sanofi K.K.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
